INO Financial Facts

Total operating expenses: 9.74M
Net loss attributable to Inovio Pharmaceuticals, Inc.: -15.45M
See Full Income Statement

Total current liabilities: 28.97M
Deferred revenue, net of current portion: 100.55K
See Full Balance Sheet

Inovio Pharma (INO) Earnings

  |   Expand Research on INO
Next EPS Date 6/12/14 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +41.7% Revenue Growth Rate +54.5% *Last Qtr.
Average % Move 1-Wk after EPS +1.5% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
3/17/14 Q413 -$0.04-$0.03 -$0.01$1.7M$1.36M N/A -25.7% Details
11/12/13 Q313 $0.00-$0.02 +$0.02$9.5M$2.99M N/A +37.6% Details
8/9/13 Q213 -$0.06N/A N/A $786K$436K N/A +35.4% Details
3/18/13 Q412 $0.00-$0.04 +$0.04$1.1M$1.08M N/A 0% Details
11/7/12 Q312 -$0.05-$0.05 $0.00$855K$2.07M N/A 0% Details
8/9/12 Q212 -$0.03-$0.04 +$0.01$436K$2.07M N/A 0% Details
5/9/12 Q112 -$0.06-$0.04 -$0.02$1.7M$2.1M N/A 0% Details
3/15/12 Q411 -$0.04-$0.05 +$0.01$1.6M$2.1M N/A 0% Details